Evidence map›Paper›PMID 31026512›Full record

ArticleNanomedicine : nanotechnology, biology, and medicine2019

Harnessing the versatility of PLGA nanoparticles for targeted Cre-mediated recombination.

Ngoc B Nguyen, Cheng-Han Chen, Yulong Zhang, Peng Zhao, Benjamin M Wu, Reza Ardehali

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomedicine : nanotechnology, biology, and medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Nanotechnological approaches for pentamidine delivery.Drug delivery and translational research · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ngoc B NguyenDivision of Cardiology, Department of Internal Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, Los Angeles, CA; Molecular, Cellular and Integrative Physiology Graduate Program, University of California, Los Angeles, Los Angeles, CA, USA.
Cheng-Han ChenDivision of Cardiology, Department of Internal Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, Los Angeles, CA; Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA, USA.
Yulong ZhangDepartment of Bioengineering, University of California, Los Angeles, Los Angeles, CA, USA.
Peng ZhaoDivision of Cardiology, Department of Internal Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, Los Angeles, CA.
Benjamin M WuDepartment of Bioengineering, University of California, Los Angeles, Los Angeles, CA, USA.
Reza ArdehaliDivision of Cardiology, Department of Internal Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, Los Angeles, CA; Molecular, Cellular and Integrative Physiology Graduate Program, University of California, Los Angeles, Los Angeles, CA, USA; Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA, USA. Electronic address: RArdehali@mednet.ucla.edu.

Funding

Exploring heterogeneity of cardiac fibroblasts to reverse fibrosisDP2HL127728 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARDEHALI, REZA · 2014 to 2014
$2.3M
Protective Effects of Neonatal Plasma in Ischemic Heart DiseaseF31HL144057 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NGUYEN, NGOC BAO · 2018 to 2020
$115k
NHLBI NIH HHS DP2 HL127728NHLBI NIH HHS F31 HL144057
6 · The paper itself

Abstract

Ligand-dependent Cre recombinases are pivotal tools for the generation of inducible somatic mutants. This method enables spatial and temporal control of gene activity through tamoxifen administration, providing new avenues for studying gene function and establishing animal models of human diseases. While this paved the way for developmental studies previously deemed impractical, the generation of tissue-specific transgenic mouse lines can be time-consuming and costly. Herein, we design a 'smart', biocompatible, and biodegradable nanoparticle system encapsulated with tamoxifen that is actively targeted to specific cell types in vivo through surface conjugation of antibodies. We demonstrate that these nanoparticles bind to cells of interest and activate Cre recombinase, resulting in tissue-specific Cre activation. This system provides a versatile, yet powerful approach to induce recombination in a ubiquitious Cre system for various biomedical applications and sets the stage for a time- and cost-effective strategy of generating new transgenic mouse lines.

Indexed as

Recombination, GeneticAnimalsAntibodiesDNADrug Delivery SystemsIntegrasesMacrophagesMice, TransgenicMonocytesNanoparticlesPolylactic Acid-Polyglycolic Acid CopolymerTamoxifenAntibodiesCre recombinaseDNAIntegrasesPolylactic Acid-Polyglycolic Acid CopolymerTamoxifen4-hydroxytamoxifenAntibody surface conjugationClonal analysisCre-mediated recombinationPLGA nanoparticles

Identifiers

PMID31026512
PMCPMC6599573

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.